Skip to Main Content

Paper Details

Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma.
0
2023
A, AZD8055, BCL-2, BCL-w, BCL-xL, BH3, BIM protein, HTDBP, MCL-1, MCL-1 protein, MPM, MPM PDX model, Malignant pleural mesothelioma, Navitoclax, PDX, cancers, mTORC1/2, malignant pleural mesothelioma, navitoclax, patient, primary MPM cells, tumors
Author NameAffiliation
Keith L LigonHarvard Medical School
Keith L LigonDana-Farber Cancer Institute
Keith L LigonCenter for Patient Derived Models, Dana-Farber Cancer Institute
Keith L LigonBrigham and Women's Hospital
Keith L LigonBroad Institute of MIT and Harvard
Raphael BuenoHarvard Medical School
Raphael BuenoBrigham and Women's Hospital
  • 1 - 7

Datasets

Release 1.2